<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196101</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 938-102</org_study_id>
    <nct_id>NCT04196101</nct_id>
  </id_info>
  <brief_title>A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects</brief_title>
  <acronym>RSVP</acronym>
  <official_title>A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to
      evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with
      RSV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects (aged 18 to 75 years, inclusive) with up to 48 hours of upper respiratory tract
      infection (URTI) symptoms who test positive for respiratory syncytial virus (RSV) and
      negative for influenza virus by rapid testing (ie, Rapid Viral Screen). Subjects with stable
      asthma or chronic obstructive pulmonary disease (COPD) will be allowed in the study.

      Approximately 70 subjects will be enrolled in this Phase 2b, randomized, double-blind,
      placebo-controlled, multicentre study of EDP-938 administered orally for the treatment of
      acute URTI with confirmed RSV infection in ambulatory adult subjects.

      For each subject, the duration of study participation will be approximately 2 weeks and will
      consist of 3 periods: Screening (occurs on Day1), Treatment (5 days), and Follow-up (9 days
      after last dose).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Symptom Score of clinical symptoms</measure>
    <time_frame>Day 1 through Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RSV RNA Viral Load</measure>
    <time_frame>Day 1 through Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by frequency of adverse events (AEs)</measure>
    <time_frame>Day 1 through Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Respiratory Syncytial Virus</condition>
  <arm_group>
    <arm_group_label>EDP-938</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take EDP-938 tablets (800 mg) once a day orally for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take EDP-938 matching placebo tablets once a day orally for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938</intervention_name>
    <description>Four tablets daily for 5 days</description>
    <arm_group_label>EDP-938</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Four tablets daily for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An informed consent document must be signed and dated by the subject

          -  Male or female individuals aged 18 to 75 years, inclusive.

          -  Up to 48 hours of URTI symptoms with at least one of the following symptoms:

        Nasal discharge, nasal congestion, malaise/tiredness, headache, sinus congestion, sneezing,
        sore throat, hoarseness, cough, shortness of breath, respiratory wheeze, earache, and/or
        symptoms of fever.

          -  Positive for RSV infection and negative for influenza virus based on rapid diagnostic.

          -  Must be willing and able to adhere to the study assessments, visit schedules,
             prohibitions, and restrictions, as described in this protocol.

        Exclusion Criteria:

          -  Clinical evidence of a lower respiratory tract infection, as determined by the
             Investigator.

          -  Anticipated need for hospitalization or emergency room care within 24 hours of
             Screening.

          -  Receipt of systemic antiviral, antibacterial, antifungal, or antimycobacterial therapy
             within 7 days of Screening and for the duration of the study

          -  Awareness of concomitant respiratory infections that are viral (other than RSV),
             bacterial, or fungal, including systemic bacterial or fungal infections, within 7 days
             of Screening.

          -  Frailty scale score ≥4 at Screening.

          -  History of chronic liver disease (eg, hemochromatosis, Wilson's disease, alpha-1
             antitrypsin deficiency, autoimmune hepatitis, nonalcoholic steatohepatitis, and/or
             alcoholic liver disease); a history of biliary disease (eg, primary sclerosing
             cholangitis, cholecystitis, choledocholithiasis); or a history of portal hypertension.
             A diagnosis of hepatic steatosis (fatty liver) is not exclusionary.

          -  Heart disease: any congenital heart disease, acute or chronic heart failure, ischemic
             heart disease, congenital long QT syndrome, or any clinical manifestation resulting in
             QT interval prolongation.

          -  Neurological and neurodevelopmental disorders (including disorders of the brain,
             spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure
             disorders], stroke, muscular dystrophy, or spinal cord injury).

          -  Malignant tumor or history of malignancy that may interfere with the aims of the study
             or a subject completing the study.

          -  Prior receipt or the subject is waiting to receive a bone marrow, stem cell, or solid
             organ transplantation.

          -  Diagnosis of cystic fibrosis.

          -  Known positive human immunodeficiency virus, active hepatitis A virus infection,
             chronic hepatitis B virus infection, and/or current or treated hepatitis C virus
             infection.

          -  Prior or planned ileal resection or bariatric surgery.

          -  Pregnant or nursing female subjects.

          -  History of alcohol addiction or current heavy alcohol use defined as: &gt;14 standard
             drinks per week and/or ≥4 standard drinks per occasion for males and &gt;7 standard
             drinks per week and/or ≥3 standard drinks per occasion for females. A standard drink
             is 12 oz of beer (5% alcohol), 5 oz table wine (12% alcohol), or 1.5 oz of spirits
             (40% alcohol).

          -  Known or suspected, in the opinion of the Investigator, renal disease or renal
             impairment.

          -  Twelve-lead ECG demonstrating a QT interval corrected for heart rate according to
             Fridericia (QTcF) that is &gt;500 msec or other clinically relevant abnormalities as
             judged by the Investigator at Screening.

          -  Use of or intention to use excluded or contraindicated medication(s) or supplements,
             including any medication known to be a moderate or potent inducer or inhibitor of the
             cytochrome P450 3A4 enzyme, within 14 days prior to Screening and for the duration of
             the study.

          -  Receipt of ≥14 days of systemic immunomodulator therapy (eg, oral corticosteroids)
             within 3 months of Screening.

          -  Prior to the first dose of study drug and during study participation, the subject has
             received any vaccine, investigational agent, or biological product within 30 days or 5
             times the half-life, whichever is longer. Note: Influenza vaccination within 7 days of
             Screening is allowed.

          -  Use of St John's wort within 28 days prior to the first dose of study drug and for the
             duration of the study.

          -  History of or currently experiencing a medical condition or any other finding
             (including laboratory test results) that, in the opinion of the Investigator, might
             confound the results of the study; pose an additional risk in administering study drug
             to the subject; could prevent, limit, or confound the protocol-specified assessments;
             or deems the subject unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Adda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eoin Coakley, MD</last_name>
    <phone>+1 617 744 3859</phone>
    <email>ecoakley@enanta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Alabama Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry McLean</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cahaba Research Inc. - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Vaughn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakeview Clinical Research</name>
      <address>
        <city>Guntersville</city>
        <state>Alabama</state>
        <zip>35976</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Nixon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Clinical Research</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Keech</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diagnamics Inc.</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramin Farsad</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allianz Research Institute Inc</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Pham</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Raikhel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dream Team Clinical Research - ClinEdge-PPDS</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quang Vo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riverside Clinical Research</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Chang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Community Research of South Florida</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Carpio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cuesta Torres</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Phase Facility Research LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Santander</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keila Hoover</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute of South Florida Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Sotolongo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Institute For Clinical Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Humberto Cruz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ormond Beach Clinical Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Torres</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research, LLC</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Haffizulla</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research - ClinEdge - PPDS</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mira Baron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Georgia Clinical Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bram Wieskopf</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Rincon</city>
        <state>Georgia</state>
        <zip>31326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Mascolo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta - ERN-PPDS</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Segall, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigators Research Group, LLC</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Maynard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedPharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Jeanfreau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Stanley Walker, MD, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Walker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Tillinghast</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montana Medical Research</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Sellman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pioneer Clinical Research LLC</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darin Gregory</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Harper</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Clinical Research Inc</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bouda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research-(Omaha Nebraska)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Essink</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Estevez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Burke Primary Care</name>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glenn Gould</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Research Center</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Jones</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Progressive Medicine of the Triad, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rosen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Horizons Clinical Research - Velocity</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Gottschlich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo Institute of Clinical Research</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed Rehman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma Institute of Allergy and Asthma Clinical Research LLC</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Darter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seetharaman Subramaniam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryce Palchick</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research, LLC</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <zip>15478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Goisse</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VitaLink Research - Upstate - PPDS</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Godwin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VitaLink Research - Spartanburg - PPDS</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Feldman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Medicine Associates of Texas - Hunt - PPDS</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Stewart</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FMC Science</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Cain</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies Inc</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Solis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ACRC Trials - MRA - PPDS</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhavi Ampajwala</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sherman Clinical Research</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muqdad Zuriqat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Plunkett</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Principle Research Solutions</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Gleason</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paratus Central Coast</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bluewater Clinical Research Group</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T4 X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John O'Mahony</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albion Finch Medical Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Gupta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alpha Clinical Research, LLC</name>
      <address>
        <city>Quebec</city>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmin Belle Isle</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RSV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

